A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate

被引:28
|
作者
Serra-Guillen, C. [1 ]
Nagore, E. [1 ]
Hueso, L. [1 ]
Llombart, B. [1 ]
Requena, C. [1 ]
Sanmartin, O. [1 ]
Botella-Estrada, R. [1 ]
Guillen, C. [1 ]
机构
[1] Inst Valenciano Oncol, Dept Dermatol, Valencia 46009, Spain
关键词
SQUAMOUS-CELL CARCINOMA; FOLLOW-UP; CRYOTHERAPY; METAANALYSIS; MULTICENTER; PAIN; 5-FLUOROURACIL; EXTREMITIES; MANAGEMENT; EFFICACY;
D O I
10.1111/j.1365-2133.2010.10098.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>Background Photodynamic therapy (PDT) and imiquimod are two excellent treatments for actinic keratosis but are often not well tolerated by patients. Objectives To ascertain which treatment is better tolerated and which produces greater patient satisfaction. A secondary objective was to determine the factors related to the patient's tolerance to each treatment. Methods Patients with at least five actinic keratosis lesions on the face and scalp were selected. The patients were randomized to receive treatment with PDT with methyl aminolaevulinate or treatment with imiquimod. Tolerance, satisfaction and predisposition to repeat the treatment were evaluated. Results Most patients exhibited good or acceptable tolerance to both PDT and imiquimod treatment. There was a higher percentage of patients treated with PDT (93%) who were very satisfied compared with imiquimod (62%) (P = 0 center dot 004). Most patients treated with either one of the two options would repeat the same treatment. No significant relationship was found between age, sex, working time exposed to the sun, phototype and hair colour and the tolerance to both treatments. Conclusions Both PDT and imiquimod are treatments that are generally well tolerated. While both treatments provide a high level of satisfaction, PDT appears to be slightly superior in this regard.
引用
收藏
页码:429 / 433
页数:5
相关论文
共 49 条
  • [21] Results of an Investigator-Initiated Single-Blind Split-Face Comparison of Photodynamic Therapy and 5% Imiquimod Cream for the Treatment of Actinic Keratoses
    Hadley, Jason
    Tristani-Firouzi, Payam
    Hull, Christopher
    Florell, Scott
    Cotter, Murray
    Hadley, Michael
    DERMATOLOGIC SURGERY, 2012, 38 (05) : 722 - 727
  • [22] Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients
    Tanaka, Noriko
    Ohata, Chika
    Ishii, Norito
    Imamura, Kazuko
    Ueda, Akihiro
    Furumura, Minao
    Yasumoto, Shinichiro
    Kawakami, Tamihiro
    Tsuruta, Daisuke
    Hashimoto, Takashi
    JOURNAL OF DERMATOLOGY, 2013, 40 (12) : 962 - 967
  • [23] Cost Effectiveness of Imiquimod 5% Cream Compared with Methyl Aminolevulinate-Based Photodynamic Therapy in the Treatment of Non-Hyperkeratotic, Non-Hypertrophic Actinic (Solar) Keratoses A Decision Tree Model
    Wilson, Edward C. F.
    PHARMACOECONOMICS, 2010, 28 (11) : 1055 - 1064
  • [24] Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12-month follow-up results of a randomized, intra-individual comparative analysis
    Sotiriou, E.
    Evangelou, G.
    Papadavid, E.
    Apalla, Z.
    Vrani, F.
    Vakirlis, E.
    Panagiotou, M.
    Stefanidou, M.
    Pombou, T.
    Krasagakis, K.
    Rigopoulos, D.
    Ioannides, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (04) : 595 - 600
  • [25] Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial
    Gebauer, K.
    Shumack, S.
    Cowen, P. S. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (04) : 897 - 903
  • [26] Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study
    Wiegell, S. R.
    Fabricius, S.
    Gniadecka, M.
    Stender, I. M.
    Berne, B.
    Kroon, S.
    Andersen, B. L.
    Mork, C.
    Sandberg, C.
    Ibler, K. S.
    Jemec, G. B. E.
    Brocks, K. M.
    Philipsen, P. A.
    Heydenreich, J.
    Haedersdal, M.
    Wulf, H. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (06) : 1327 - 1332
  • [27] Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes
    Logan, Ian T.
    Kulakov, Elizabeth L.
    Perrett, Conal M.
    DERMATOLOGIC SURGERY, 2020, 46 (10) : 1272 - 1278
  • [28] A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis
    Dirschka, T.
    Ekanayake-Bohlig, S.
    Dominicus, R.
    Aschoff, R.
    Herrera-Ceballos, E.
    Botella-Estrada, R.
    Hunfeld, A.
    Kremser, M.
    Schmitz, B.
    Luebbert, H.
    Puig, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (02) : 288 - 297
  • [29] Combined daylight and conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis of the face and scalp: a new and efficient approach
    Salido-Vallejo, Rafael
    Jimenez-Najar, F.
    Garnacho-Sucedo, G.
    Velez, A.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2020, 312 (09) : 675 - 680
  • [30] Comparative Study of Photodynamic Therapy with Topical Methyl Aminolevulinate versus 5-Aminolevulinic Acid for Facial Actinic Keratosis with Long-Term Follow-Up
    Ko, Dong-Yeob
    Kim, Ki-Ho
    Song, Ki-Hoon
    ANNALS OF DERMATOLOGY, 2014, 26 (03) : 321 - 331